Analysts expect Cerner Co. (NASDAQ:CERN) to announce sales of $1.44 billion for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have made estimates for Cerner’s earnings, with the lowest sales estimate coming in at $1.43 billion and the highest estimate coming in at $1.45 billion. Cerner posted sales of $1.39 billion in the same quarter last year, which suggests a positive year over year growth rate of 3.6%. The business is scheduled to issue its next quarterly earnings report on Thursday, April 23rd.

On average, analysts expect that Cerner will report full year sales of $5.89 billion for the current financial year, with estimates ranging from $5.85 billion to $5.97 billion. For the next year, analysts forecast that the firm will post sales of $6.17 billion, with estimates ranging from $6.00 billion to $6.33 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Cerner.

Cerner (NASDAQ:CERN) last announced its quarterly earnings data on Tuesday, February 4th. The company reported $0.75 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.01. Cerner had a return on equity of 16.66% and a net margin of 9.30%. The firm had revenue of $1.44 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter in the prior year, the firm posted $0.63 earnings per share. Cerner’s revenue for the quarter was up 5.6% compared to the same quarter last year.

Several analysts have issued reports on the company. Cfra upped their price objective on Cerner from $72.00 to $76.00 and gave the company a “hold” rating in a research note on Wednesday, February 5th. UBS Group assumed coverage on Cerner in a research note on Tuesday, November 26th. They set a “buy” rating and a $84.00 price objective on the stock. Robert W. Baird upped their price objective on Cerner from $72.00 to $85.00 and gave the company an “outperform” rating in a research note on Wednesday, February 5th. BidaskClub upgraded Cerner from a “sell” rating to a “hold” rating in a research report on Thursday, February 6th. Finally, Canaccord Genuity increased their price target on Cerner from $80.00 to $81.00 and gave the stock a “buy” rating in a research report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $78.71.

NASDAQ CERN traded down $2.69 on Monday, hitting $73.38. 2,778,430 shares of the stock traded hands, compared to its average volume of 1,917,046. The stock has a 50-day moving average of $75.38 and a 200 day moving average of $70.83. Cerner has a twelve month low of $54.22 and a twelve month high of $80.90. The company has a market capitalization of $23.73 billion, a P/E ratio of 44.47, a price-to-earnings-growth ratio of 1.94 and a beta of 0.97. The company has a current ratio of 2.04, a quick ratio of 2.02 and a debt-to-equity ratio of 0.24.

In related news, EVP Randy D. Sims sold 188,780 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $80.00, for a total value of $15,102,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Michael R. Battaglioli sold 10,000 shares of the stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $79.40, for a total value of $794,000.00. Following the completion of the transaction, the chief accounting officer now directly owns 8,726 shares of the company’s stock, valued at $692,844.40. The disclosure for this sale can be found here. Insiders sold a total of 392,180 shares of company stock valued at $31,200,356 over the last three months. Corporate insiders own 0.75% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Harrington Investments INC boosted its stake in Cerner by 0.6% during the 4th quarter. Harrington Investments INC now owns 22,645 shares of the company’s stock valued at $1,662,000 after purchasing an additional 140 shares in the last quarter. Destination Wealth Management boosted its stake in Cerner by 2.9% during the 4th quarter. Destination Wealth Management now owns 5,312 shares of the company’s stock valued at $390,000 after purchasing an additional 148 shares in the last quarter. Wetherby Asset Management Inc. boosted its stake in Cerner by 5.5% during the 3rd quarter. Wetherby Asset Management Inc. now owns 3,330 shares of the company’s stock valued at $227,000 after purchasing an additional 174 shares in the last quarter. Synovus Financial Corp boosted its stake in Cerner by 0.6% during the 4th quarter. Synovus Financial Corp now owns 30,684 shares of the company’s stock valued at $2,256,000 after purchasing an additional 175 shares in the last quarter. Finally, Prestige Wealth Management Group LLC boosted its stake in Cerner by 11.2% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,894 shares of the company’s stock valued at $139,000 after purchasing an additional 190 shares in the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

Cerner Company Profile

Cerner Corporation provides health care information technology solutions and tech-enabled services in the United States and internationally. The company offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers.

Read More: Trading Ex-Dividend Strategy

Get a free copy of the Zacks research report on Cerner (CERN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cerner (NASDAQ:CERN)

Receive News & Ratings for Cerner Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerner and related companies with MarketBeat.com's FREE daily email newsletter.